MX2022000394A - Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. - Google Patents

Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.

Info

Publication number
MX2022000394A
MX2022000394A MX2022000394A MX2022000394A MX2022000394A MX 2022000394 A MX2022000394 A MX 2022000394A MX 2022000394 A MX2022000394 A MX 2022000394A MX 2022000394 A MX2022000394 A MX 2022000394A MX 2022000394 A MX2022000394 A MX 2022000394A
Authority
MX
Mexico
Prior art keywords
cancer
inhibitor
treatment
orally administered
administered paclitaxel
Prior art date
Application number
MX2022000394A
Other languages
English (en)
Inventor
Min-Fun Rudolf Kwan
E Douglas Kramer
Cheung- Tak HUNG
Christopher Glyn Charles Alexander Jackson
Paul William Glue
Jr Gerald J Fetterly
Original Assignee
Athenex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Therapeutics Ltd filed Critical Athenex Therapeutics Ltd
Publication of MX2022000394A publication Critical patent/MX2022000394A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La solicitud se refiere a combinaciones farmacéuticas de paclitaxel administrado por vía oral y un inhibidor de P-gp; las combinaciones farmacéuticas son adecuadas para el tratamiento del cáncer en un sujeto y para reducir o prevenir la toxicidad, reacciones de infusión de tipo de hipersensibilidad y otros resultados negativos resultantes o asociados con terapia de paclitaxel administrado por vía intravenosa (por ejemplo, Taxol(r) o paclitaxel formulado con Cremophor(r)) en un sujeto que padece cáncer.
MX2022000394A 2015-07-21 2018-01-19 Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. MX2022000394A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562195243P 2015-07-21 2015-07-21

Publications (1)

Publication Number Publication Date
MX2022000394A true MX2022000394A (es) 2022-02-10

Family

ID=57833861

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000872A MX2018000872A (es) 2015-07-21 2016-07-21 Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
MX2022000394A MX2022000394A (es) 2015-07-21 2018-01-19 Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000872A MX2018000872A (es) 2015-07-21 2016-07-21 Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.

Country Status (10)

Country Link
US (2) US20180207148A1 (es)
EP (1) EP3324968B1 (es)
CN (2) CN115778956A (es)
AU (3) AU2016295357B2 (es)
CA (1) CA2993127C (es)
HK (1) HK1256017A1 (es)
JO (1) JO3737B1 (es)
MX (2) MX2018000872A (es)
TW (1) TWI760306B (es)
WO (1) WO2017013490A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US20190314361A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA
WO2020124070A1 (en) * 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
TW202320748A (zh) * 2021-09-10 2023-06-01 美商亞瑟尼克斯公司 用於治療固態腫瘤之口服投予的紫杉醇、Ｐ－ｇｐ抑制劑和檢查點抑制劑之治療組合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030448A1 (en) * 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
WO2003094967A2 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
KR100557093B1 (ko) * 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US20190314361A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA

Also Published As

Publication number Publication date
US20180207148A1 (en) 2018-07-26
AU2023229590A1 (en) 2023-10-05
EP3324968A4 (en) 2019-04-10
EP3324968B1 (en) 2023-09-27
CA2993127A1 (en) 2017-01-26
MX2018000872A (es) 2018-08-15
CA2993127C (en) 2023-10-17
WO2017013490A2 (en) 2017-01-26
WO2017013490A3 (en) 2017-03-02
JO3737B1 (ar) 2021-01-31
AU2016295357A1 (en) 2018-02-15
EP3324968A2 (en) 2018-05-30
AU2021209160A1 (en) 2021-08-19
AU2016295357B2 (en) 2021-05-13
EP3324968C0 (en) 2023-09-27
TWI760306B (zh) 2022-04-11
CN108135895A (zh) 2018-06-08
HK1256017A1 (zh) 2019-09-13
US20230172926A1 (en) 2023-06-08
CN115778956A (zh) 2023-03-14
TW201716064A (zh) 2017-05-16

Similar Documents

Publication Publication Date Title
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
TW201613578A (en) Pharmaceutical combinations
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
EA201590325A1 (ru) Улучшенные способы лечения рака с пониженной почечной токсичностью
MX2015016893A (es) Combinacion de ro5503781 y capecitabina para la terapia para el cancer.
NZ723303A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
UA95037U (uk) Спосіб лікування неалкогольного стеатогепатиту
UA105586U (uk) Спосіб лікування печінкової енцефалопатії